To avoid potentially diminishing a patient’s chance of response, many physicians have begun using growth factors such as recombinant human erythropoietin (rHuEPO) off-label to manage anaemia in hepatitis C with the objective of maintaining the RBV dose.40 The rHuEPO agents are the biosintetic form of the hormone EPO. This evidence concerns the gene EPO and hepatitis C virus infection.